title: Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine.
abstract: OBJECTIVE
  To compare the efficacy and safety of cholestyramine, an anion exchange resin, and pravastatin, a new hydrophilic specific inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in the treatment of heterozygous familial hypercholesterolaemia.
  
  
  METHODS
  Double blind, double dummy, placebo controlled study with three parallel groups.
  
  
  METHODS
  Six specialist lipid clinics in the United Kingdom.
  
  
  METHODS
  128 patients aged 18-70 with heterozygous familial hypercholesterolaemia diagnosed on strict biochemical and clinical findings.
  
  
  METHODS
  Total plasma cholesterol, triglyceride, and lipoprotein subfractions and biochemical and haematological safety parameters.
  
  
  RESULTS
  Pravastatin (40 mg/day) led to a 25% reduction in total plasma cholesterol concentration and a reduction in low density lipoprotein cholesterol concentration of 30%. Cholestyramine (24 g/day) led to similar reductions in concentrations of total cholesterol (23%) and low density lipoprotein cholesterol (31%). No consistent changes occurred in high density lipoprotein cholesterol values with either compound. Plasma triglyceride concentrations showed a small rise (18%) on resin therapy. No serious adverse drug reactions occurred during the study.
  
  
  CONCLUSIONS
  Pravastatin seems to be a highly effective, well tolerated drug for severe hypercholesterolaemia. Patients chosen for this study were recruited on the basis that they could tolerate a full dose of cholestyramine, and in this situation cholestyramine was also highly effective in lowering plasma low density lipoprotein cholesterol concentrations.
authors.affiliation: University College and Middlesex School of Medicine, Middlesex Hospital, London.
authors.forename: D J
authors.initials: DJ
authors.lastname: Betteridge
authors.forename: D
authors.initials: D
authors.lastname: Bhatnager
authors.forename: R F
authors.initials: RF
authors.lastname: Bing
authors.forename: P N
authors.initials: PN
authors.lastname: Durrington
authors.forename: G R
authors.initials: GR
authors.lastname: Evans
authors.forename: H
authors.initials: H
authors.lastname: Flax
authors.forename: R H
authors.initials: RH
authors.lastname: Jay
authors.forename: N
authors.initials: N
authors.lastname: Lewis-Barned
authors.forename: J
authors.initials: J
authors.lastname: Mann
authors.forename: D R
authors.initials: DR
authors.lastname: Matthews
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002792:Cholestyramine Resin / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides; D002792:Cholestyramine Resin; D017035:Pravastatin